By Denny Jacob
Scientific instruments maker Bruker said it disagreed with a court ruling in a patent infringement case between its NanoString business and 10x Genomics.
Todd Garland, president of Bruker spatial biology division, said the company expects to promptly seek a stay of any injunction that is finally ordered in the case involving NanoString's GeoMx products.
"We also look forward to the appeal of our case being heard by the U.S. Court of Appeals for the Federal Circuit, a court that specializes in patent disputes," he added.
10x Genomics on Monday said the U.S. District Court for the District of Delaware ruled against the GeoMx products sold by Bruker.
The injunction, which the court said it will enter in January, is expected to prohibit Bruker from making, selling, using or offering to sell in the United States its GeoMx digital spatial profiler and associated instruments for RNA and protein detection, the company added. 10x Genomics also said the court affirmed the $31 million damages awarded by a jury in November 2023, as well as supplemented damages and interest that will be added to the total damages when the final judgment is entered.
The ruling follows the November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 24, 2024 10:19 ET (15:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。